Cancer-detection system wins S'pore firm top Asian Innovation Award

Cancer-detection system wins S'pore firm top Asian Innovation Award
Clearbridge BioMedics founder Mr Johnson Chen (left) and Professor Lim Chwee Teck, Professor Principal Investigator, Mechanobiology Institute, at the Asian Innovation Awards ceremony in Hong Kong.

SINGAPORE - Singapore firm Clearbridge BioMedics, known for developing cancer-detecting technology ClearCell, has won three awards at the Asian Innovation Awards 2012, including the Gold Prize, the Technopreneur of the Year award and the Audience Choice Award.

The Asian Innovation Awards is an annual ceremony held by Wall Street Journal Asia to recognise innovations that use unconventional processes to improve quality of life or productivity.

A spin-off company from National University of Singapore (NUS), Clearbridge BioMedics beat 11 other finalists shortlisted from over 240 applications with its work on cancer detection technology.

Its proprietary ClearCell System is able to effectively detect, isolate and retrieve wholly-intact circulating tumour cells from patients' blood samples.

This has numerous applications in the areas of cancer screening, diagnosis and treatment monitoring.

The ClearCell System has achieved International Organisation for Standardisation certification for medical devices, and is already available on the cancer research market.

Founder Mr Johnson Chen said: "This fantastic win is a validation of our work, and for the need to find better ways to diagnose, treat and conduct research on cancer."

"We aim to further develop our ClearCell System into a healthcare solution that will empower cancer clinicians and researchers to manage cancer in a more effective manner," he added.

This year's Asian Innovation Awards was jointly held by the Wall Street Journal and Credit Suisse.

ljessica@sph.com.sg

Purchase this article for republication.

BRANDED CONTENT

SPONSORED CONTENT

Your daily good stuff - AsiaOne stories delivered straight to your inbox
By signing up, you agree to our Privacy policy and Terms and Conditions.